Funda Meric-Bernstam MD

Surgical Oncology (Other than Breast)

Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy Nellie B. Connally Chair in Breast Cancer Research Professor, Division of Cancer Medicine and Surgery

Join to View Full Profile

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 713-745-7296

Education & Training

University of MichiganResidency, Surgery, 1991 - 1998
Yale School of MedicineClass of 1991

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 1999 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
WA State Medical License 2023 - 2025
MI State Medical License 1996 - 2000
American Board of Preventive Medicine Clinical Informatics
American Board of Surgery Surgery
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

Bevacizumab in Multiple Phase I Combinations Start of enrollment: 2007 Oct 10
Completed
Phase 1
Axillary Reverse Mapping for Invasive Carcinoma of the Breast Start of enrollment: 2008 Mar 01
Completed
Phase 1
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy Start of enrollment: 2009 Mar 30
ACTIVE_NOT_RECRUITING
PHASE2
Fluorescent Dyes for Lymph Node Mapping Start of enrollment: 2010 Mar 01
Completed
Phase 1
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer Start of enrollment: 2011 Jan 05
Completed
Phase 1
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer Start of enrollment: 2011 Mar 01
Completed
Phase 2
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program Start of enrollment: 2012 Mar 01
RECRUITING
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Start of enrollment: 2013 Oct 01
Terminated
Phase 2
A Study of TAS-120 in Patients With Advanced Solid Tumors Start of enrollment: 2014 Jul 21
COMPLETED
PHASE1, PHASE2
Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19
RECRUITING
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 01
Terminated
Phase 1, Phase 2
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors Start of enrollment: 2019 Jan 24
ACTIVE_NOT_RECRUITING
PHASE1
A Study in Patients With Advanced Cancers Start of enrollment: 2022 Mar 25
RECRUITING
PHASE1, PHASE2
Roles: Contact
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression Start of enrollment: 2021 Sep 21
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
APPROVED_FOR_MARKETING
Roles: Contact
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers Start of enrollment: 2023 Jan 11
RECRUITING
PHASE1
Roles: Contact
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer Start of enrollment: 2020 Oct 15
TERMINATED
PHASE1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances.
Lorenzo Guidi, Julian Etessami, Carmine Valenza, Augusto Valdivia, Funda Meric-Bernstam
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2025-06-01
1 citations
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.
Ana Oaknin, Jung-Yun Lee, Vicky Makker, Do-Youn Oh, Susana Banerjee
Advances in Therapy. 2025-05-01
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
Mohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, Timothy A Yap, Jordi Rodon
Clinical Cancer Research. 2025-04-01

Lectures

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
2019 ASCO Annual Meeting - 6/1/2019
Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Single agent activity of ZW25, a HER's targeted bispecific antibody, in heavily pretreated HERs' expressing cancers.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Symposia on Cancer Research 2013
The University of Texas, M. D. Anderson Cancer Center, Houston, Texas - 10/4/2013
Symposia on Cancer Research 2013
The University of Texas, M. D. Anderson Cancer Center, Houston, Texas - 10/4/2013
Somatic Mutation Testing and Opportunities for Clinical Interventions
Houston, TX - 10/28/2014
Join now to see all

Press Mentions

MD Anderson Unveils Breakthrough Research Findings – February 10, 2025February 10th, 2025
Novel ADC AZD8205 Demonstrates Manageable Safety Profile and Preliminary Efficacy in First-in-Human TrialSeptember 13th, 2024
MD Anderson Research Highlights for May 8, 2024May 8th, 2024
Join now to see all

Grant Support

Training of Academic Surgical OncologistsUNIVERSITY OF TX MD ANDERSON CAN CTR1994–2028
A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)METHODIST HOSPITAL RESEARCH INSTITUTE2022–2027
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffoldUNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR2022–2027
Texas EXperimental Cancer Therapeutics Network - TEX CTNUNIVERSITY OF TX MD ANDERSON CAN CTR2014–2026